Diabetic Retinopathy Should Not Be a Contraindication to Thrombolytic Therapy for Acute Myocardial Infarction: Review of Ocular Hemorrhage Incidence and Location in the GUSTO-I Trial fn1fn1This study was supported by Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genentech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.
- 12 December 1997
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 30 (7) , 1606-1610
- https://doi.org/10.1016/s0735-1097(97)00394-x
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- ACC/AHA guidelines for the management of patients with acute myocardial infarctionJournal of the American College of Cardiology, 1996
- Mersey has changed its policyBMJ, 1995
- Thrombolysis in patients with diabetesBMJ, 1995
- Acute Myocardial Infarction in Diabetic Patients in the Thrombolytic EraDiabetic Medicine, 1994
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agentsJournal of the American College of Cardiology, 1993
- Intraocular Hemorrhage Associated with Intravenously Administered StreptokinaseAmerican Journal of Ophthalmology, 1991
- Retinal haemorrhage after thrombolytic therapyThe Lancet, 1991
- Guidelines for the early management of patients with acute myocardial infarctionJournal of the American College of Cardiology, 1990
- If Nothing Goes Wrong, Is Everything All Right?JAMA, 1983